Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Irish Stock Exchange  >  Elan Corporation, plc    ELN   IE0003072950

ELAN CORPORATION, PLC (ELN)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Elan Outlines Spending Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 05:16pm CEST

Irish drug maker Elan Corp. (>> Elan Corporation, plc) Friday said it would return $1 billion to shareholders, refinance debt and make acquisitions following the recent $3.25 billion sale of its stake in multiple sclerosis drug Tysabri to partner Biogen Idec Inc. (>> Biogen Idec Inc.).

Larger U.S. peer Biogen Idec agreed two weeks ago to acquire the 50% of Tysabri it didn't own from Elan, leaving questions over the future structure of the Irish company. Tysabri was Elan's largest drug, accounting for most of its revenue.

Elan, based in Ireland but with significant operations in the U.S., said at the time of the Tysabri transaction it would receive a royalty of 12% of Tysabri's global net sales for the first 12 months after the deal is completed.

"By unlocking a portion of the Tysabri asset value while retaining a significant earnings upside, we have a unique opportunity to reward shareholders, diversify our business and create a highly distinctive business platform upon which to advance to the benefit of shareholders and patients around the world," Elan Chief Executive Kelly Martin said.

The company plans to provide further detail on its acquisition and refinancing plans after the expected closure of the Tysabri deal after the second quarter, an Elan spokesman said. Mr. Martin wasn't available for further comment. Elan has traditionally focused on therapies for the central nervous system.

The company had around $600 million in long-term debt by the end of December 2012.

Deutsche Bank said that though the share buyback was welcome, significant questions remain over the structure of Elan in the future.

"Close to 40% of Elan's current market cap could be invested in as-yet unknown assets and as such, we are unlikely to gain the visibility needed to become constructive on the shares until transactions are concluded," analyst Richard Parkes said in a note.

Biogen, through the Tysabri acquisition, is betting that regulators will approve expanded use of the drug and help to bolster the company's already strong position in the lucrative MS market.

Although Tysabri is considered an effective and promising drug, the partnership between Biogen and Elan on its marketing has had a difficult history. Biogen suspended Tysabri in the U.S. in 2005 after two patients using combination therapy contracted a rare brain infection. Tysabri was approved in the U.S. and EU primarily as a single-use drug a year later.

Elan shares climbed following the announcement Friday.

Write to Jessica Hodgson at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Elan Corporation, plc, Biogen Idec Inc.
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN 0.16% 297.34 Delayed Quote.-6.86%
ELAN CORPORATION, PLC 0.00% 12.71 End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELAN CORPORATION, PLC
2014With eye on tax rates, Horizon Pharma buys Ireland's Vidara
RE
2013Ex-SAC manager Martoma fails to end part of insider case
RE
2013ELAN CORPORATION, PLC : Perrigo Company and Elan Corporation Plc Receive Irish H..
PU
2013Ex-SAC trader points to Cohen testimony in insider trading case
RE
2013ELAN CORPORATION, PLC : Elan Announces Shareholder Approval of its Acquisition b..
BU
2013ELAN CORPORATION, PLC : Elan wins shareholder approval to complete Perrigo sale
RE
2013The prosecutors with SAC Capital in their crosshairs
RE
2013OZ MANAGEMENT LP 3Q 13F : Largest Sales
DJ
2013OZ MANAGEMENT LP 3Q 13F : Holdings As Of Sep 30 -2-
DJ
2013OZ MANAGEMENT LP 3Q 13F : Holdings As Of Sep 30
DJ
More news
News from SeekingAlpha
2017Early Beginnings For Alzheimer's Vaccines 
Chart ELAN CORPORATION, PLC
Duration : Period :
Elan Corporation, plc Technical Analysis Chart | ELN | IE0003072950 | 4-Traders
Sector and Competitors
1st jan.Capitalization (M$)
ELAN CORPORATION, PLC0.00%0
CELLTRION, INC.--.--%33 593
IQVIA HOLDINGS INC7.88%21 859
LONZA GROUP2.81%19 855
INCYTE CORPORATION-22.94%15 470
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 517